Related Experiment Video

Updated: Mar 26, 2026

Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

29.2K

The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study

Gianluca Lista1, Laura Fabbri, Renáta Polackova

  • 1Department of Neonatology, Ospedale dei Bambini x2018;V. Buzzi' - ICP, Milan, Italy.

Neonatology
|January 29, 2016
PubMed

Insights

Pharmaceutical-grade caffeine citrate is safe and effective for treating apnea of prematurity in preterm infants. This real-world study confirms its benefits and manageable side effects in routine clinical use.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Clinical Research

Background:

  • Caffeine citrate is the standard treatment for apnea of prematurity (AOP).
  • Real-world data on pharmaceutical-grade caffeine citrate (Peyona) utilization and safety is needed.
  • Postauthorization safety studies are requested by regulatory agencies.

Purpose of the Study:

  • To evaluate the clinical use, outcomes, and safety of pharmaceutical-grade caffeine citrate.
  • To assess its effectiveness in preterm infants with gestational age <37 weeks.
  • To gather real-world evidence on drug safety and efficacy.

Main Methods:

  • A multicenter, noninterventional, prospective study was conducted across five European countries.
  • 506 preterm infants (<37 weeks gestational age) received pharmaceutical-grade caffeine citrate.
  • Data on drug administration, indications, treatment duration, and outcomes were collected.

Main Results:

  • The primary indication was AOP treatment (58%) and prophylaxis (37%), with a median treatment duration of 21 days.
  • AOP resolution was the main reason for study termination (80%).
  • Adverse drug reactions were infrequent (4.2%), with tachycardia being the most common (2.3%). Serious adverse events were rare (one case of seizures). Hepatic or renal functional impairment occurred in 8.1% but was manageable.

Conclusions:

  • Pharmaceutical-grade caffeine citrate is safe for managing apnea of prematurity in real-world clinical practice.
  • The study confirms the drug's benefit for preterm infants.
  • Adverse events were generally manageable, indicating a favorable safety profile.
Abstract

More Related Videos

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.9K
Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates05:58

Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates

Published on: September 6, 2017

41.1K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
733
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
370
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
328
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
697